Read by QxMD icon Read


Andrea Farolfi, Francesco Ceci, Paolo Castellucci, Tiziano Graziani, Giambattista Siepe, Alessandro Lambertini, Riccardo Schiavina, Filippo Lodi, Alessio G Morganti, Stefano Fanti
PURPOSE: The primary aim of this retrospective, single-centre analysis was to assess the performance of 68 Ga-PSMA-11 PET/CT in prostate cancer (PCa) patients in early PSA failure after radical prostatectomy (RP). The secondary aim was to assess the potential impact of 68 Ga-PSMA-11 PET/CT on treatment strategy. METHODS: 68 Ga-PSMA-11 PET/CT is performed in our institution within an investigational new drug (IND) trial in PCa patients with biochemical recurrence (BCR)...
June 15, 2018: European Journal of Nuclear Medicine and Molecular Imaging
Thomas Langbein, Guillaume Chaussé, Richard P Baum
No abstract text is available yet for this article.
June 14, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Sebastian Hoberück, Enrico Michler, Daniel Kaiser, Anne Röhnert, Klaus Zöphel, Jörg Kotzerke
A 79-year old man with prostate cancer under active surveillance for 5 years was referred for a PSMA-PET/MRI for re-evaluation because of a rising prostate-specific antigen value. PET/MRI revealed a ribbonlike tracer accumulation in a healing fracture of the distal radius. This case illustrates that PSMA expression may occur in healing bone fractures in the distal radius. It can be assumed that benign causes of tracer accumulations in the upper extremities are missed in PET/CT due to elevated position of the arms during image acquisition...
June 12, 2018: Clinical Nuclear Medicine
Priyanka Verma, Gaurav Malhotra, Ritesh Agrawal, Sunita Sonavane, Vilas Meshram, Ramesh V Asopa
PURPOSE OF THE REPORT: Prostate-specific membrane antigen (PSMA) overexpression is not restricted to prostate cancer, but it has also been demonstrated in gliomas, lung cancer, and in tumor neovasculature. Systematic studies exploring PSMA uptake in thyroid tumors are lacking. The aim of this pilot study was to assess PSMA expression in patients with metastatic differentiated thyroid cancer (mDTC). MATERIALS AND METHODS: Ten patients of mDTC harboring 32 lesions (5 men; age range, 38-65 years; mean age, 50 years) underwent prospective evaluation with radioiodine (I), F-FDG PET, and Ga-PSMA-HBED-CC PET scans as per the institution protocol...
June 12, 2018: Clinical Nuclear Medicine
Simona Dostalova, Hana Polanska, Marketa Svobodova, Jan Balvan, Olga Krystofova, Yazan Haddad, Sona Krizkova, Michal Masarik, Tomas Eckschlager, Marie Stiborova, Zbynek Heger, Vojtech Adam
Herein, we describe the in vivo effects of doxorubicin (DOX) encapsulated in ubiquitous protein apoferritin (APO) and its efficiency and safety in anti-tumor treatment. APODOX is both passively (through Enhanced Permeability and Retention effect) and actively targeted to tumors through prostate-specific membrane antigen (PSMA) via mouse antibodies conjugated to the surface of horse spleen APO. To achieve site-directed conjugation of the antibodies, a HWRGWVC heptapeptide linker was used. The prostate cancer-targeted and non-targeted nanocarriers were tested using subcutaneously implanted LNCaP cells in athymic mice models, and compared to free DOX...
June 11, 2018: Scientific Reports
Wilhem Leconet, He Liu, Ming Guo, Sophie Le Lamer-Déchamps, Charlotte Molinier, Sae Kim, Tjasa Vrlinic, Murielle Oster, Fang Liu, Vincent Navarro, Jaspreet S Batra, Adolfo Lopez-Noriega, Sylvestre Grizot, Neil H Bander
Small therapeutic proteins represent a promising novel approach to treat cancer. Nevertheless, their clinical application is often adversely impacted by their short plasma half-life. Controlled long-term delivery of small biologicals has become a challenge because of their hydrophilic properties and in some cases their limited stability. Here, an in-situ forming depot injectable polymeric system was used to deliver BiJ591, a Bispecific T-cell Engager (BiTE) targeting both prostate-specific membrane antigen (PSMA) and the CD3 T-cell receptor in prostate cancer...
June 11, 2018: Molecular Cancer Therapeutics
Helle D Zacho, Julie B Nielsen, Ali Afshar-Oromieh, Uwe Haberkorn, Nandita deSouza, Katja De Paepe, Katja Dettmann, Niels C Langkilde, Christian Haarmark, Rune V Fisker, Dennis T Arp, Jesper Carl, Jørgen B Jensen, Lars J Petersen
PURPOSE: To prospectively compare diagnostic accuracies for detection of bone metastases by 68 Ga-PSMA PET/CT, 18 F-NaF PET/CT and diffusion-weighted MRI (DW600 -MRI) in prostate cancer (PCa) patients with biochemical recurrence (BCR). METHODS: Sixty-eight PCa patients with BCR participated in this prospective study. The patients underwent 68 Ga-PSMA PET/CT, a 18 F-NaF PET/CT and a DW600 -MRI (performed in accordance with European Society of Urogenital Radiology guidelines, with b values of 0 and 600 s/mm2 )...
June 6, 2018: European Journal of Nuclear Medicine and Molecular Imaging
Kristen A Wangerin, Lucia Baratto, Mohammad Mehdi Khalighi, Thomas A Hope, Praveen K Gulaka, Timothy W Deller, Andrei H Iagaru
OBJECTIVE: Gallium-68-labeled radiopharmaceuticals pose a challenge for scatter estimation because their targeted nature can produce high contrast in these regions of the kidneys and bladder. Even small errors in the scatter estimate can result in washout artifacts. Administration of diuretics can reduce these artifacts, but they may result in adverse events. Here, we investigated the ability of algorithmic modifications to mitigate washout artifacts and eliminate the need for diuretics or other interventions...
June 6, 2018: AJR. American Journal of Roentgenology
Kambiz Rahbar, Ali Afshar-Oromieh, Hossein Jadvar, Hojjat Ahmadzadehfar
Prostate-specific membrane antigen (PSMA) is a promising target for imaging diagnostics and targeted radionuclide therapy (theranostics) of prostate cancer and its metastases. There is increasing evidence of encouraging response rates and a low toxicity profile of radioligand therapy (RLT) of metastatic castration-resistant prostate cancer using 177 Lu-labeled PSMA ligands. In this article, we review the current status of diagnostics and therapy using radiolabeled PSMA ligands. We also suggest protocols for patient selection criteria and conduct of PSMA-based RLT...
January 2018: Molecular Imaging
Jörg Kotzerke, Dirk Böhmer, Thorsten Schlomm, Thomas Maurer, Ambros J Beer, Heinz Schmidberger
The debate refers the known evidence for PSMA-PET/CT in biochemical recurrence of prostate cancer and consider carefully interdisciplinary in which situation which patient needs imaging to choose the adequate therapeutic option. General aspects for the care of cancer patients are taken into consideration.
June 2018: Nuklearmedizin. Nuclear Medicine
Bettina Beuthien-Baumann, Stefan A Koerber
The integration of data from positron-emission-tomography, combined with computed tomography as PET/CT or combined with magnet resonance imaging as PET/MRI, into radiation treatment planning of prostate cancer is gaining higher impact with the development of more sensitive and specific radioligands. The classic PET-tracer for prostate cancer imaging are [11C]choline and [11C]acetate, which are currently outperformed by ligands binding to the prostate-specific- membrane-antigen (PSMA). [68Ga]PSMA-11, which is the most frequently applied tracer, has shown to detect lymph node metastases, local recurrences, distant metastases and intraprostatic foci with high sensitivity, even at relatively low PSA levels...
June 4, 2018: Quarterly Journal of Nuclear Medicine and Molecular Imaging
Zhantong Wang, Orit Jacobson, Rui Tian, Ronnie C Mease, Dale Kiesewetter, Gang Niu, Martin G Pomper, Xiaoyuan Chen
Several radioligands targeting prostate-specific membrane antigen (PSMA) have been clinically introduced as a new class of radiotheranostics for the treatment of prostate cancer. Among them, (((R)-1-carboxy-2-mcercaptoethyl)carbamoyl)-L-glutamic acid (MCG) has been successfully labeled with radioisotopes for prostate cancer imaging. The aim of this study is to conjugate MCG with an albumin binding moiety to further improve the in vivo pharmacokinetics. METHODS: MCG was conjugated with an Evans blue (EB) derivative for albumin binding and a DOTA chelator...
June 4, 2018: Bioconjugate Chemistry
I Berger, C Annabattula, J Lewis, D V Shetty, J Kam, F Maclean, M Arianayagam, B Canagasingham, R Ferguson, M Khadra, R Ko, M Winter, H Loh, C Varol
BACKGROUND: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) can be used to locate lesions based on PSMA avidity, however guidelines on its use are limited by its infancy. We aimed to compare multiparametric magnetic resonance imaging (mpMRI) and PSMA PET/CT to prostatectomy histopathology. METHODS: We conducted a chart review from February 2015 to January 2017 of 50 male patients staged for prostate cancer using PSMA PET/CT and mpMRI who then underwent radical prostatectomy...
June 1, 2018: Prostate Cancer and Prostatic Diseases
Kay M Westenfelder, Beatrice Lentes, Julia Rackerseder, Nassir Navab, Jürgen E Gschwend, Matthias Eiber, Tobias Maurer
No abstract text is available yet for this article.
May 29, 2018: Clinical Genitourinary Cancer
Urs J Muehlematter, Niels J Rupp, Julian Mueller, Daniel Eberli, Irene A Burger
Multiparametric MRI incorporating T2-weighted, diffusion-weighted, and dynamic contrast material-enhanced sequences is currently used for detection and localization of clinically important prostate cancer (PCa). The Ga-labeled PET tracer targeting the prostate-specific membrane antigen (PSMA, Ga-PSMA-11) is a promising diagnostic approach for staging and restating PCa. Recent studies suggest that Ga-PSMA could also be used for primary PCa detection and localization. We report a case of a Ga-PSMA PET/MR-positive lesion of the peripheral zone in a 73-year-old man with a negative preceding multiparametric MRI...
May 25, 2018: Clinical Nuclear Medicine
Liran Domachevsky, Natalia Goldberg, Hanna Bernstine, Meital Nidam, David Groshar
OBJECTIVES: To quantitatively characterize clinically significant intra-prostatic cancer (IPC) by prostate-specific membrane antigen (PSMA) expression and cell density on PSMA-11 positron emission tomography/magnetic resonance (PET/MR). METHODS: Retrospective study approved by the institutional review board with informed written consent obtained. Patients with a solitary, biopsy-proven prostate cancer, Gleason score (GS) ≥7, presenting for initial evaluation by PET/computerised tomography (PET/CT), underwent early prostate PET/MR immediately after PSMA-11 tracer injection...
May 30, 2018: European Radiology
Christopher C Kloss, Jihyun Lee, Aaron Zhang, Fang Chen, Jan Joseph Melenhorst, Simon F Lacey, Marcela V Maus, Joseph A Fraietta, Yangbing Zhao, Carl H June
Cancer has an impressive ability to evolve multiple processes to evade therapies. While immunotherapies and vaccines have shown great promise, particularly in certain solid tumors such as prostate cancer, they have been met with resistance from tumors that use a multitude of mechanisms of immunosuppression to limit effectiveness. Prostate cancer, in particular, secretes transforming growth factor β (TGF-β) as a means to inhibit immunity while allowing for cancer progression. Blocking TGF-β signaling in T cells increases their ability to infiltrate, proliferate, and mediate antitumor responses in prostate cancer models...
May 8, 2018: Molecular Therapy: the Journal of the American Society of Gene Therapy
Ganesan Vaidyanathan, Choong Mo Kang, Darryl McDougald, Il Minn, Mary Brummet, Martin G Pomper, Michael R Zalutsky
INTRODUCTION: Radiolabeled, low-molecular-weight prostate-specific membrane antigen (PSMA) inhibitors based on the Glu-ureido pharmacophore show promise for the detection and treatment of castration-resistant prostate cancer; however, high renal retention of activity, related in part to overexpression of PSMA in kidneys can be problematic. The goal of the current study was to investigate the use of brush border enzyme-cleavable linkers as a strategy for reducing kidney activity levels from radiolabeled PSMA inhibitors...
May 5, 2018: Nuclear Medicine and Biology
Christian Mair, Boris Warwitz, Katharina Fink, Lorenza Scarpa, Bernhard Nilica, Johanna Maffey-Steffan, Sabine Buxbaum, Irene J Virgolini
PURPOSE: As radionuclide therapy is gaining importance in palliative treatment of patients suffering from neuroendocrine tumour (NET) as well as castration resistant prostate cancer (CRPC), the radiation protection of patients, staff, family members and the general public is of increasing interest. Here, we determine patient discharge dates according to European guidelines. METHODS: In 40 patients with NET and 25 patients with CRPC organ and tumour doses based on the MIRD concept were calculated from data obtained during the first therapy cycle...
May 23, 2018: Annals of Nuclear Medicine
Mark Thalgott, Charlotte Düwel, Isabel Rauscher, Matthias M Heck, Bernhard Haller, Andrei Gafita, Jürgen E Gschwend, Markus Schwaiger, Tobias Maurer, Matthias Eiber
Our aim was to assess the diagnostic potential of one-stop shop Prostate-specific membrane antigen-ligand Positron Emission Tomography/Magnetic Resonance Imaging (68 Ga-PSMA-11 PET/MRI) compared to preoperative staging nomograms in patients with high-risk prostate cancer (PC). Methods: A total of 102 patients underwent 68 Ga-PSMA-11 PET/MRI before intended radical prostatectomy (RP) with lymph node dissection. Preoperative variables determined the probabilities for lymph node metastases (LNM), extracapsular extension (ECE) and seminal vesical involvement (SVI) using the Memorial Sloan-Kettering Cancer Center (MSKCC) nomogram and Partin tables...
May 24, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"